145 related articles for article (PubMed ID: 31240576)
1. Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection.
Abdullatif HM; Ramzi R; Mogahed EA; Ghobrial CM; El Rasheed Abd El Zaher BA; El Raziky MS; El-Karaksy HM
Clin Drug Investig; 2019 Sep; 39(9):857-864. PubMed ID: 31240576
[TBL] [Abstract][Full Text] [Related]
2. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
Liu CH; Yu ML; Peng CY; Hsieh TY; Huang YH; Su WW; Cheng PN; Lin CL; Lo CC; Chen CY; Chen JJ; Ma Q; Brooks-Rooney C; Kao JH
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1290-1300. PubMed ID: 30362139
[TBL] [Abstract][Full Text] [Related]
3. Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass.
Johnson SW; Teachey AL; Valanejad SM; Griffin SM; Weber SF
J Clin Pharm Ther; 2017 Oct; 42(5):624-626. PubMed ID: 28474386
[TBL] [Abstract][Full Text] [Related]
4. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
Shiha G; Esmat G; Hassany M; Soliman R; Elbasiony M; Fouad R; Elsharkawy A; Hammad R; Abdel-Razek W; Zakareya T; Kersey K; Massetto B; Osinusi A; Lu S; Brainard DM; McHutchison JG; Waked I; Doss W
Gut; 2019 Apr; 68(4):721-728. PubMed ID: 29666174
[TBL] [Abstract][Full Text] [Related]
5. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
Bourgeois S; Horsmans Y; Nevens F; van Vlierberghe H; Moreno C; Beumont M; Vijgen L; van Eygen V; Luo D; Hillewaert V; Van Remoortere P; van de Logt J; Ouwerkerk-Mahadevan S
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971875
[TBL] [Abstract][Full Text] [Related]
7. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
8. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
Murray KF; Balistreri WF; Bansal S; Whitworth S; Evans HM; Gonzalez-Peralta RP; Wen J; Massetto B; Kersey K; Shao J; Garrison KL; Parhy B; Brainard DM; Arnon R; Gillis LA; Jonas MM; Lin CH; Narkewicz MR; Schwarz K; Rosenthal P
Hepatology; 2018 Dec; 68(6):2158-2166. PubMed ID: 30070726
[TBL] [Abstract][Full Text] [Related]
10. Generic Ledipasvir-Sofosbuvir Treatment for Adolescents With Chronic Hepatitis C Virus Infection.
Fouad HM; Sabry MA; Ahmed A; Hassany M; Al Soda MF; Abdel Aziz H
J Pediatric Infect Dis Soc; 2020 Jul; 9(3):386-389. PubMed ID: 31310312
[TBL] [Abstract][Full Text] [Related]
11. Sexual Dysfunction in a Patient Taking Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C: A Case Report.
Lenz DU; Crutcher EL; Greene EM
J Pharm Pract; 2019 Apr; 32(2):231-235. PubMed ID: 29183252
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
[TBL] [Abstract][Full Text] [Related]
13. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Kan H; Imamura M; Kawakami Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Aikata H; Hayes CN; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Med Virol; 2017 Nov; 89(11):1963-1972. PubMed ID: 28657143
[TBL] [Abstract][Full Text] [Related]
14. Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus-infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir.
El-Karaksy H; Mogahed EA; Abdullatif H; Ghobrial C; El-Raziky MS; El-Koofy N; El-Shabrawi M; Ghita H; Baroudy S; Okasha S
J Pediatr Gastroenterol Nutr; 2018 Nov; 67(5):626-630. PubMed ID: 30216203
[TBL] [Abstract][Full Text] [Related]
15. [Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].
Quintero J; Juampérez J; Julio E; Cabello V; Mercadal-Hally M; Soler-Palacín P; Segarra Ó; Rodrigo C
An Pediatr (Engl Ed); 2019 Mar; 90(3):141-147. PubMed ID: 30126773
[TBL] [Abstract][Full Text] [Related]
16. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
18. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Kowdley KV; Gordon SC; Reddy KR; Rossaro L; Bernstein DE; Lawitz E; Shiffman ML; Schiff E; Ghalib R; Ryan M; Rustgi V; Chojkier M; Herring R; Di Bisceglie AM; Pockros PJ; Subramanian GM; An D; Svarovskaia E; Hyland RH; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Pound D; Fried MW;
N Engl J Med; 2014 May; 370(20):1879-88. PubMed ID: 24720702
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.
German P; Mathias A; Brainard D; Kearney BP
Clin Pharmacokinet; 2016 Nov; 55(11):1337-1351. PubMed ID: 27193156
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.
Gupta N; Mbituyumuremyi A; Kabahizi J; Ntaganda F; Muvunyi CM; Shumbusho F; Musabeyezu E; Mukabatsinda C; Ntirenganya C; Van Nuil JI; Kateera F; Camus G; Damascene MJ; Nsanzimana S; Mukherjee J; Grant PM
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):119-126. PubMed ID: 30552056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
